Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VaxInnate makes promotions

This article was originally published in Scrip

Executive Summary

VaxInnate, a biotechnology firm developing a new vaccine technology, has announced two strategic promotions and two additions to its senior development team to help drive growth of the company's pipeline. Dr Lynda Tussey has been promoted to chief scientific officer from vice-president of R&D, while Bruce Weaver has been named vice-president of manufacturing following his time as director of process development. Also Dr Peter Fusco has joined the company as vice-president of R&D, and Dr Stephen Haworth has assumes the role of vice-president of clinical. Mr Weaver, Dr Fusco and Dr Haworth will join the company's senior management team.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts